Posted by Michael Wonder on 08 Jul 2018
Regeneron's CEO has been outspoken about drug price hikes, but one of his company’s drugs just got more expensive
5 July 2018 - Regeneron said Sanofi had final decision-making authority on pricing for the drug.
Regeneron CEO Leonard Schleifer once stated in a heated debate between pharmaceutical executives that he was not a fan of price hikes on prescription drugs.
"You can't say you've set a drug at a fair price [when it's launched] and then have price increases. You can't have it both ways. It's covering up for a lack of innovation," Schleifer said during the panel in December 2016.
But at the start of July, the price Dupixent, an eczema drug made by Regeneron and Sanofi increased by 3%. The drug now has a list price of $37,000 a year compared to when it was first cleared at $30,000 a year.
